New cocktail therapy takes on tough lymphoma

NCT ID NCT05182957

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining an immunotherapy drug (anti-PD-1) with two chemotherapy-like drugs (lenalidomide and azacitidine) can shrink tumors in people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 31 participants will receive the three drugs in cycles. The main goal is to see how many patients achieve a complete or partial response after six cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-PD-1 monoclonal antibody, lenalidomide, and azacitidine
What this could lead to: If successful, this combination could offer a new treatment option for patients with hard-to-treat peripheral T-cell lymphoma that has not responded to standard therapies.
What could go wrong: This is a small, early-phase (phase 2) trial with only 31 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not a cure—patients may still need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.